Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (noting a discrepancy with the request metadata which listed "Gyre Therapeutics, Inc.") on November 2, 2022. The filing addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's continued listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a stock price compliance issue.
Material Changes
- Stock Price Deficiency: The company received a notice that its common stock closing bid price was below $1.00 for 30 consecutive trading days.
- Listing Status: The company is currently non-compliant with Nasdaq Marketplace Rule 5550(a)(2) (Minimum Bid Price Requirement).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has 180 calendar days (until May 1, 2023) to regain compliance.
- Remediation Path: Compliance is achieved if the closing bid price is at or above $1.00 per share for a minimum of 10 consecutive trading days before the deadline.
- Extension Possibility: If compliance is not met by May 1, 2023, Nasdaq may grant a second 180-day grace period, provided the company meets other listing standards (e.g., market value of publicly-held shares) and notifies Nasdaq of its intent to cure.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting. The company would be entitled to appeal such a determination.
- Uncertainty: Management states there can be no assurance that the company will regain compliance or maintain other listing requirements.
Investor Verification Checklist
- Verify the current trading price of Catalyst Biosciences (CBIO) to assess proximity to the $1.00 threshold.
- Monitor the company's stock performance over the next 10 consecutive trading days to determine if the initial compliance window is met.
- Review the company's market value of publicly-held shares to ensure eligibility for a potential second grace period.
- Watch for future 8-K filings regarding the outcome of the compliance period or any appeal to a Nasdaq hearings panel.